InflaRx (IFRX) Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IFRX Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
InflaRx N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.91 |
| 52 Week High | US$1.94 |
| 52 Week Low | US$0.71 |
| Beta | 1.53 |
| 1 Month Change | -2.32% |
| 3 Month Change | -17.10% |
| 1 Year Change | -20.70% |
| 3 Year Change | -52.99% |
| 5 Year Change | -77.43% |
| Change since IPO | -93.92% |
Recent News & Updates
Recent updates
Here's Why We're A Bit Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Situation
Feb 06
InflaRx: Gohibic Remains Niche, INF904 Underwhelms, Cash Burn Accelerates (Rating Downgrade)
Nov 20Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
Jul 10InflaRx (NASDAQ:IFRX) Will Have To Spend Its Cash Wisely
Jun 25We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Dec 23InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 17We're A Little Worried About InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Mar 28Can InflaRx (NASDAQ:IFRX) Afford To Invest In Growth?
Nov 30InflaRx seeks FDA emergency use nod for its treatment for critically ill COVID-19 patients
Sep 29InflaRx reports Q2 results
Aug 05InflaRx stock rises 13% on plans to file EUA for COVID drug in US for critically ill patients
Jul 26Here's Why We're Watching InflaRx's (NASDAQ:IFRX) Cash Burn Situation
Jul 16InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder
Jul 06InflaRx granted FDA Type B meeting to discuss submissions for COVID therapy
Jun 29Is InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?
Apr 01Our First Look At InflaRx
Dec 29Estimating The Fair Value Of InflaRx N.V. (NASDAQ:IFRX)
Dec 15InflaRx (NASDAQ:IFRX) Is In A Good Position To Deliver On Growth Plans
Aug 27InflaRx And Vilobelimab In AAV: Avoiding Clinical Hard Knocks
Aug 25We Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business Growth
May 01Do Institutions Own InflaRx N.V. (NASDAQ:IFRX) Shares?
Mar 02We're Keeping An Eye On InflaRx's (NASDAQ:IFRX) Cash Burn Rate
Jan 08
Shareholder Returns
| IFRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.0% | -0.7% | -1.9% |
| 1Y | -20.7% | 21.6% | 14.4% |
Return vs Industry: IFRX underperformed the US Biotechs industry which returned 23.9% over the past year.
Return vs Market: IFRX underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| IFRX volatility | |
|---|---|
| IFRX Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: IFRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IFRX's weekly volatility has decreased from 17% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 74 | Niels Riedemann | www.inflarx.de |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications.
InflaRx N.V. Fundamentals Summary
| IFRX fundamental statistics | |
|---|---|
| Market cap | US$67.23m |
| Earnings (TTM) | -US$52.55m |
| Revenue (TTM) | US$33.78k |
Is IFRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IFRX income statement (TTM) | |
|---|---|
| Revenue | €29.33k |
| Cost of Revenue | €7.27m |
| Gross Profit | -€7.24m |
| Other Expenses | €38.40m |
| Earnings | -€45.63m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | -24,677.94% |
| Net Profit Margin | -155,582.08% |
| Debt/Equity Ratio | 0% |
How did IFRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/27 20:13 |
| End of Day Share Price | 2026/03/27 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
InflaRx N.V. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Mayur Somaiya | BMO Capital Markets Equity Research |
| Madhu Kumar | B. Riley Securities, Inc. |